37 studies found for:    " June 06, 2012":" July 06, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" June 06, 2012":" July 06, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (37 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: darunavir (PREZISTA);   Drug: etravirine (INTELENCE);   Drug: ritonavir;   Drug: Other antiretroviral medications
2 Enrolling by invitation Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
Condition: HIV Infections
Intervention: Drug: No Investigational Product
3 Recruiting Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
Condition: HIV Infections
Interventions: Drug: Dapivirine;   Drug: Placebo
4 Recruiting Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study
Conditions: HIV Infection;   Healthy
Intervention:
5 Enrolling by invitation Positive Change Agents Program-Tanzania (Evaluation)
Condition: HIV Infection
Intervention: Behavioral: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
6 Recruiting Bone Health and Vitamin D Status
Conditions: Osteopenia;   Vitamin D Deficiency;   HIV Infection
Intervention:
7 Recruiting Clinical Trial to Reduce Drinking in Women With HIV
Condition: HIV Infection
Interventions: Drug: Naltrexone;   Drug: Placebo
8 Enrolling by invitation Minority AIDS Initiative Retention and Re-Engagement Project
Condition: HIV/AIDS
Intervention: Behavioral: Enhanced Peer Intervention
9 Active, not recruiting MARCH Central Nervous System Substudy
Condition: HIV-1 Infection
Interventions: Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors;   Drug: Arm 2 Maraviroc and Protease Inhibitors;   Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
10 Completed Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Condition: HIV-1 Infection
Interventions: Drug: Vacc-C5/GM-CSF;   Drug: Vacc-C5/Alhydrogel
11 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
12 Recruiting Evaluating the Response to Three Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Lopinavir/ritonavir;   Drug: Efavirenz;   Drug: Raltegravir
13 Active, not recruiting Evaluation of Barriers to Postpartum Care in HIV Infected Women
Conditions: HIV Infection;   Pregnancy
Intervention: Other: questionaires and structured interviews
14 Active, not recruiting A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Condition: HIV Infections
Interventions: Drug: MK-1439;   Drug: Efavirenz;   Drug: TRUVADA®
15 Completed A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Drug: saquinavir [Invirase];   Drug: ritonavir;   Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
16 Completed
Has Results
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: TUMS® Ultra Strength;   Drug: MINTOX® Maximum Strength
17 Active, not recruiting Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Condition: HIV Infections
Intervention: Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
18 Recruiting A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
Condition: HIV-1 Infection
Interventions: Drug: Darunavir;   Drug: Etravirine;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Raltegravir;   Drug: Second line ART regimens are usually based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs);   Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available;   Other: SOC adherence versus SOC+CPI adherence
19 Recruiting Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
Conditions: HIV-1 Infection;   Pf Subclinical Parasitemia
Interventions: Drug: Lopinavir/ritonavir;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz;   Drug: Nevirapine;   Drug: emtricitabine/tenofovir disoproxil fumarate;   Drug: trimethoprim/sulfamethoxazole
20 Completed Multidisciplinary Services to Enhance HIV Testing and Linkage to Care Among MSM
Conditions: HIV Testing;   Linkage to Care
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results
Indicates status has not been verified in more than two years